GH Research logo

GH Research

GHRS | NASDAQ
Chart Builder DCF Calculator
$18.75
-$0.35 (-1.83%)
At close: Nov 16, 2026, 4:00 PM ET
$18.75
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-1.83%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
25.4
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #922/1021 (Top 90%)

Key Statistics

Market Data

Market Cap $1.29B
1D Range
18.27 19.49
52W Range
12.49 30.64

Valuation (TTM)

PE -18.75
PB 3.58
EV/EBITDA -14.99

Valuation (NTM)

Forward PE N/A
Forward PEG -0.68
Price Target $40.00
Loading financial charts...

Profile

GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy...

Sector Healthcare
Industry Biotechnology
Employees 73
IPO Date Jun 25, 2021
Fiscal Year January - December

Latest News

GH Research Reports Third Quarter 2026 Financial Results and Provides Business Update

3 days ago · globenewswire.com

GH Research Reports Third Quarter 2026 Financial Results and Provides Business Update
GH Research Announces Appointment of Vanina Popova, MD, as Chief Development Officer

3 days ago · globenewswire.com

GH Research Announces Appointment of Vanina Popova, MD, as Chief Development Officer
GH Research Remains Undervalued Ahead Of Pivotal Phase III Program

25 days ago · seekingalpha.com

GH Research Remains Undervalued Ahead Of Pivotal Phase III Program
GH Research: 'Buy' GH001 TRD Advancement Presses On And Expansion Opportunities

2 months ago · seekingalpha.com

GH Research: 'Buy' GH001 TRD Advancement Presses On And Expansion Opportunities
GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update

3 months ago · globenewswire.com

GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update
Psychedelics guidance from the FDA set to benefit developers, including AtaiBeckley, Jefferies says

4 months ago · proactiveinvestors.com

Psychedelics guidance from the FDA set to benefit developers, including AtaiBeckley, Jefferies says
GH Research Announces Publication of Phase 2a Postpartum Depression Results

6 months ago · globenewswire.com

GH Research Announces Publication of Phase 2a Postpartum Depression Results
GH Research: Rapid Onset And Short Action Change The Treatment Paradigm

6 months ago · seekingalpha.com

GH Research: Rapid Onset And Short Action Change The Treatment Paradigm
These Analysts Revise Their Forecasts On GH Research After Q1 Results

6 months ago · benzinga.com

These Analysts Revise Their Forecasts On GH Research After Q1 Results
GH Research Reports First Quarter 2026 Financial Results and Provides Business Update

6 months ago · globenewswire.com

GH Research Reports First Quarter 2026 Financial Results and Provides Business Update

Analyst Summary

# of Analysts
7
Consensus
Buy
Price Target
$40.00
Upside
+113.33%
Buy (7)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.